Posted by Michael Wonder on 31 Oct 2023
End of temporary funding of palivizumab for preventing RSV
31 October 2023 - Palivizumab has been funded for the last two seasons from funding made available as part of the response to COVID-19 and its impacts.
PHARMAC used the ring-fenced COVID-19 treatment budget to pay for palivizumab, which was separate from the Combined Pharmaceutical Budget.
